<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04081961</url>
  </required_header>
  <id_info>
    <org_study_id>PMI.IIS.2016.1.</org_study_id>
    <nct_id>NCT04081961</nct_id>
  </id_info>
  <brief_title>Feasibility Study to Use Biosensing Devices to Monitor PA and Resp. Function in Smokers w and w/o Resp. Symptoms/COPD</brief_title>
  <official_title>A Proof-of-concept, Open-label, Feasibility Study to Evaluate Mobile Applications and Biosensing (mHealth) Devices to Monitor Physical Activity and Respiratory Function in Smokers With and Without Respiratory Symptoms/COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kazakhstan Academy of Preventive Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Philip Morris International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Synergy Research Group Kazakhstan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kazakhstan Academy of Preventive Medicine</source>
  <brief_summary>
    <textblock>
      This study examines the feasibility and acceptability of using mobile applications and
      biosensing (mHealth) devices in detecting vitality parameters in current smokers with and
      without respiratory symptoms/COPD (e.g., heart rate, blood oxygenation, steps/motion) for a
      future big-scale study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to investigate feasibility of using mHealth devices to improve the
      treatment, assessment, compliance, and outcomes in smokers with and without respiratory
      symptoms/COPD. The study aims to reveal and address the anticipated barriers to the
      acceptance and implementation of mHealth devices in this patient population and clinical
      setting. As is well documented, the more attention patients receive from medical personnel,
      the better their clinical outcomes. Here we are attempting to use device-driven monitoring
      applications, interactive reminders, and teaching modules to deliver a constant positive
      feedback loop to patients to improve their health decisions.

      Objectives of the study:

      To assess the feasibility of using mHealth devices in current smokers with and without
      respiratory symptoms/COPD.

      To assess the utility (i.e., validity and reproducibility) of mHealth devices in detecting
      vitality parameters in current smokers with and without respiratory symptoms/COPD (e.g.,
      heart rate; blood oxygenation; steps/motion; FEV1, FVC, and their ratio; peak expiratory flow
      [PEF]).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 7, 2019</start_date>
  <completion_date type="Actual">October 31, 2019</completion_date>
  <primary_completion_date type="Actual">October 10, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Recruitment</measure>
    <time_frame>Baseline</time_frame>
    <description>Recruitment is defined as the number of potential participants screened for study eligibility versus the number of persons who enrolled in the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Retention</measure>
    <time_frame>through study completion, an average of 90 days</time_frame>
    <description>Retention is defined as the proportion of participants enrolled who completed the intervention and all study measures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Protocol Adherence</measure>
    <time_frame>through study completion, an average of 90 days</time_frame>
    <description>Adherence to the study protocol is determined as the proportion of participants enrolled from whom all mHealth parameters registered every day.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">27</enrollment>
  <condition>Signs and Symptoms, Respiratory</condition>
  <condition>Mobile Applications</condition>
  <condition>Activity Trackers</condition>
  <condition>Respiratory Function Tests</condition>
  <arm_group>
    <arm_group_label>Asymptomatic current smokers</arm_group_label>
    <description>No respiratory symptoms and preserved pulmonary function based on spirometry (FEV1/FVC of at least 0.70 after bronchodilation treatment and FVC ≥80% of the expected value)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Grey zone&quot; current smokers</arm_group_label>
    <description>Initially preserved pulmonary function based on spirometry, but with clinical symptoms based on COPD Assessment Test (CAT≥10) and results of the 6-min walk test (6 MWT) less than 450 meters.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Current smokers with COPD</arm_group_label>
    <description>Current smokers with a confirmed diagnosis of COPD (GOLD stage I-III)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Anamed OEM device; Air Next mobile spirometry device</intervention_name>
    <description>Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device</description>
    <arm_group_label>&quot;Grey zone&quot; current smokers</arm_group_label>
    <arm_group_label>Asymptomatic current smokers</arm_group_label>
    <arm_group_label>Current smokers with COPD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Residents of City of Almaty aged 40-59 who smoke conventional cigarettes with a minimum of
        10 pack-year smoking history
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current smokers who are currently smoking conventional cigarettes with a minimum of 10
             pack-year smoking history

          -  Able to use and willing to be trained to use mHealth devices

        Exclusion Criteria:

          -  COPD exacerbation that has not resolved at least 28 days prior to screening

          -  COPD exacerbation occurring after screening but before the first study visit

          -  Pneumonia or other respiratory tract infections that have not resolved at least 14
             days prior to screening

          -  Pneumonia occurring after screening but before the first study visit

          -  Active respiratory disorders: tuberculosis, lung cancer, significant bronchiectasis,
             sarcoidosis, bronchial asthma, lung fibrosis, pulmonary hypertension, interstitial
             lung diseases, or other active pulmonary diseases

          -  Any co-morbid medical condition that in the opinion of the investigator would make
             participation in the study unsafe or unfeasible, including conditions that prohibit
             completion of exercise testing

          -  Use of supplemental oxygen therapy

          -  Inability to abstain from smoking during the period in which the participant is
             admitted to the Kazakhstan Academy of Preventive Medicine (KAPM) COPD Center

          -  A history of allergy or hypersensitivity to metal, particularly stainless steel

          -  Any vital sign indicator, for example, hypertension or tachycardia at rest that, at
             the discretion of the investigator, would make participation in the study unsafe or
             unfeasible

          -  Women who test positive for pregnancy during screening, lactating women, or women
             planning on becoming pregnant during the study

          -  Participants using assistive devices like walking aids, as these are likely to
             interfere with physical activity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Almaz Sharman, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kazakhstan Academy of Preventive Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kazakhstan Academy of Preventive Medicine</name>
      <address>
        <city>Almaty</city>
        <zip>050008</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kazakhstan</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <results_first_submitted>December 18, 2019</results_first_submitted>
  <results_first_submitted_qc>December 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 9, 2020</results_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Signs and Symptoms, Respiratory</mesh_term>
    <mesh_term>Signs and Symptoms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The dataset after the re-identification will be available to other researchers on the 'www.intervals.science' platform.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available after May 1, 2020 without time limit.</ipd_time_frame>
    <ipd_url>http://www.intervals.science</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT04081961/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT04081961/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Asymptomatic Current Smokers</title>
          <description>No respiratory symptoms and preserved pulmonary function based on spirometry (FEV1/FVC of at least 0.70 after bronchodilation treatment and FVC ≥80% of the expected value)
Anamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device</description>
        </group>
        <group group_id="P2">
          <title>“Grey Zone” Current Smokers</title>
          <description>Initially preserved pulmonary function based on spirometry, but with clinical symptoms based on COPD Assessment Test (CAT≥10) and results of the 6-min walk test (6 MWT) less than 450 meters.
Anamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device</description>
        </group>
        <group group_id="P3">
          <title>Current Smokers With COPD</title>
          <description>Current smokers with a confirmed diagnosis of COPD (GOLD stage I–III)
Anamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Asymptomatic Current Smokers</title>
          <description>No respiratory symptoms and preserved pulmonary function based on spirometry (FEV1/FVC of at least 0.70 after bronchodilation treatment and FVC ≥80% of the expected value)
Anamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device</description>
        </group>
        <group group_id="B2">
          <title>“Grey Zone” Current Smokers</title>
          <description>Initially preserved pulmonary function based on spirometry, but with clinical symptoms based on COPD Assessment Test (CAT≥10) and results of the 6-min walk test (6 MWT) less than 450 meters.
Anamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device</description>
        </group>
        <group group_id="B3">
          <title>Current Smokers With COPD</title>
          <description>Current smokers with a confirmed diagnosis of COPD (GOLD stage I–III)
Anamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="9"/>
                    <count group_id="B4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.9" lower_limit="44" upper_limit="58"/>
                    <measurement group_id="B2" value="50.8" lower_limit="42" upper_limit="58"/>
                    <measurement group_id="B3" value="51.4" lower_limit="44" upper_limit="59"/>
                    <measurement group_id="B4" value="51.0" lower_limit="42" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="9"/>
                    <count group_id="B4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Kazakhstan</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="9"/>
                    <count group_id="B4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Recruitment</title>
        <description>Recruitment is defined as the number of potential participants screened for study eligibility versus the number of persons who enrolled in the study.</description>
        <time_frame>Baseline</time_frame>
        <population>The number of potential participants screened for study eligibility</population>
        <group_list>
          <group group_id="O1">
            <title>Asymptomatic Current Smokers</title>
            <description>No respiratory symptoms and preserved pulmonary function based on spirometry (FEV1/FVC of at least 0.70 after bronchodilation treatment and FVC ≥80% of the expected value)
Anamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device</description>
          </group>
          <group group_id="O2">
            <title>“Grey Zone” Current Smokers</title>
            <description>Initially preserved pulmonary function based on spirometry, but with clinical symptoms based on COPD Assessment Test (CAT≥10) and results of the 6-min walk test (6 MWT) less than 450 meters.
Anamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device</description>
          </group>
          <group group_id="O3">
            <title>Current Smokers With COPD</title>
            <description>Current smokers with a confirmed diagnosis of COPD (GOLD stage I–III)
Anamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Recruitment</title>
          <description>Recruitment is defined as the number of potential participants screened for study eligibility versus the number of persons who enrolled in the study.</description>
          <population>The number of potential participants screened for study eligibility</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Retention</title>
        <description>Retention is defined as the proportion of participants enrolled who completed the intervention and all study measures.</description>
        <time_frame>through study completion, an average of 90 days</time_frame>
        <population>Participants recruited to the study</population>
        <group_list>
          <group group_id="O1">
            <title>Asymptomatic Current Smokers</title>
            <description>No respiratory symptoms and preserved pulmonary function based on spirometry (FEV1/FVC of at least 0.70 after bronchodilation treatment and FVC ≥80% of the expected value)
Anamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device</description>
          </group>
          <group group_id="O2">
            <title>“Grey Zone” Current Smokers</title>
            <description>Initially preserved pulmonary function based on spirometry, but with clinical symptoms based on COPD Assessment Test (CAT≥10) and results of the 6-min walk test (6 MWT) less than 450 meters.
Anamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device</description>
          </group>
          <group group_id="O3">
            <title>Current Smokers With COPD</title>
            <description>Current smokers with a confirmed diagnosis of COPD (GOLD stage I–III)
Anamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Retention</title>
          <description>Retention is defined as the proportion of participants enrolled who completed the intervention and all study measures.</description>
          <population>Participants recruited to the study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Protocol Adherence</title>
        <description>Adherence to the study protocol is determined as the proportion of participants enrolled from whom all mHealth parameters registered every day.</description>
        <time_frame>through study completion, an average of 90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Asymptomatic Current Smokers</title>
            <description>No respiratory symptoms and preserved pulmonary function based on spirometry (FEV1/FVC of at least 0.70 after bronchodilation treatment and FVC ≥80% of the expected value)
Anamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device</description>
          </group>
          <group group_id="O2">
            <title>“Grey Zone” Current Smokers</title>
            <description>Initially preserved pulmonary function based on spirometry, but with clinical symptoms based on COPD Assessment Test (CAT≥10) and results of the 6-min walk test (6 MWT) less than 450 meters.
Anamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device</description>
          </group>
          <group group_id="O3">
            <title>Current Smokers With COPD</title>
            <description>Current smokers with a confirmed diagnosis of COPD (GOLD stage I–III)
Anamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device</description>
          </group>
        </group_list>
        <measure>
          <title>Protocol Adherence</title>
          <description>Adherence to the study protocol is determined as the proportion of participants enrolled from whom all mHealth parameters registered every day.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days after participant was recruited to the study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Asymptomatic Current Smokers</title>
          <description>No respiratory symptoms and preserved pulmonary function based on spirometry (FEV1/FVC of at least 0.70 after bronchodilation treatment and FVC ≥80% of the expected value)
Anamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device</description>
        </group>
        <group group_id="E2">
          <title>“Grey Zone” Current Smokers</title>
          <description>Initially preserved pulmonary function based on spirometry, but with clinical symptoms based on COPD Assessment Test (CAT≥10) and results of the 6-min walk test (6 MWT) less than 450 meters.
Anamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device</description>
        </group>
        <group group_id="E3">
          <title>Current Smokers With COPD</title>
          <description>Current smokers with a confirmed diagnosis of COPD (GOLD stage I–III)
Anamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Baurzhan Zhussupov</name_or_title>
      <organization>Kazakhstan Academy of Preventive Medicine</organization>
      <phone>87774822171</phone>
      <email>baurzhan.zhussupov@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

